Isradipine SRO in patients with hypertension and diabetes: a multicenter study

Donatella Spotti, Cristina Robba, Guido Pozza

Research output: Contribution to journalArticlepeer-review

Abstract

As many antihypertensive drugs have negative effects on glucose metabolism, we conducted a multicenter study to evaluate the efficacy of isradipine slow release oral (SRO) 5 mg/d in patients with hypertension and diabetes. A total of 111 patients (mean age, 56 years) with mild-to-moderate hypertension and non-insulin-dependent diabetes mellitus were enrolled. After a 15-day run-in period with placebo, they were treated with isradipine SRO 5 mg/d for 26 weeks. Enalapril 10 to 20 mg/d was added to the treatment at the end of the first 6 weeks if blood pressure (BP) was not adequately controlled (ie, diastolic blood pressure [DBP] ≥90 mm Hg). During each study visit (every 15 days the first 6 weeks and every 30 days thereafter) casual BP and heart rate measurements were performed. At baseline and 6 and 26 weeks, noninvasive 24-hour BP monitoring was done. Mean casual BP values, which were 163/100 mm Hg at baseline, were 10 mm Hg lower at 2 weeks; at the end of the study, systolic BP had fallen by 23 mm Hg and DBP by 16 mm Hg. Analysis of the 24-hour BP profile, at 6 and 26 weeks indicated that the physiologic circadian rhythm was maintained throughout the study, although these BP values decreased over the course of the study. BP reduction was more pronounced in the daytime (7 am to 11 pm) than the nighttime (11 pm to 7 am). Heart rate remained almost unchanged at all the observation times. Side effects, related mainly to systemic vasodilation, occurred in 12 patients, only one of whom suspended the study treatment. Overall, ten patients dropped out of the study. The main blood chemistry findings remained unchanged; microalbuminuria and glycosylated hemoglobin showed a tendency to decrease, whereas blood glucose remained virtually unchanged. These results, obtained in a large series, indicate that isradipine SRO provides gradual, uniform control of BP in hypertensive diabetic patients without negative effects on the blood glucose profile.

Original languageEnglish
Pages (from-to)190-199
Number of pages10
JournalCurrent Therapeutic Research
Volume56
Issue number2
DOIs
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Fingerprint

Dive into the research topics of 'Isradipine SRO in patients with hypertension and diabetes: a multicenter study'. Together they form a unique fingerprint.

Cite this